Renal Denervation and Symplicity HTN-3 "Dubium Sapientiae Initium" (Doubt Is the Beginning of Wisdom)

被引：37
|
作者：
Papademetriou, Vasilios [1 ,2 ]
Tsioufis, Costas [3 ]
Doumas, Michael [4 ]
机构：
[1] Vet Affairs Med Ctr, Dept Med Cardiol, Washington, DC 20422 USA
[2] Georgetown Univ, Washington, DC USA
[3] Kapodestrian Univ Athens, Dept Cardiol, Athens, Greece
[4] Aristotle Univ Thessaloniki, Dept Med, GR-54006 Thessaloniki, Greece
来源：
CIRCULATION RESEARCH | 2014年 / 115卷 / 02期
关键词：
AMBULATORY BLOOD-PRESSURE; SYMPATHETIC DENERVATION; RESISTANT HYPERTENSION; NERVE-STIMULATION; ABLATION; CATHETER; SYSTEM; FUTURE;
D O I：
10.1161/CIRCRESAHA.115.304099
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：211 / 214
页数：4
相关论文
共 50 条
  • [31] From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?
    Pathak, Atul
    Ewen, Sebastian
    Fajadet, Jean
    Honton, Benjamin
    Mahfoud, Felix
    Marco, Jean
    Schlaich, Markus
    Schmieder, Roland
    Tsioufis, Konstantinos
    Ukena, Christian
    Zeller, Thomas
    EUROINTERVENTION, 2014, 10 (01) : 21 - 23
  • [32] Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence
    Kjeldsen, Sverre E.
    Elmula, Fadl Elmula M. Fadl
    Ingrid, O. S.
    Persu, Alexandre
    Jin, Yu
    Staessen, Jan A.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2015, 1 (01) : 48 - 56
  • [33] Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3
    Kario, K.
    Bakris, G.
    Pocock, S.
    Fahy, M.
    Bhatt, D. L.
    EUROPEAN HEART JOURNAL, 2019, 40 : 664 - 664
  • [34] An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial
    Flack, John M.
    Bhatt, Deepak L.
    Kandzari, David E.
    Brown, David
    Brar, Sandeep
    Choi, James W.
    D'Agostino, Ralph
    East, Cara
    Katzen, Barry T.
    Lee, Lilian
    Leon, Martin B.
    Mauri, Laura
    O'Neill, William W.
    Oparil, Suzanne
    Rocha-Singh, Krishna
    Townsend, Raymond R.
    Bakris, George
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2015, 9 (10) : 769 - 779
  • [35] SYMPLICITY HTN-3 trial: what is it and what does it mean?
    Boehm, Michael
    Mahfoud, Felix
    EUROPEAN HEART JOURNAL, 2014, 35 (26) : 1697 - 1698
  • [36] PREFERENTIAL REDUCTION IN MORNING/NOCTURNAL HYPERTENSION BY RENAL DENERVATION FOR DRUG-RESISTANT HYPERTENSION: A NEW ABPM ANALYSIS OF SYMPLICITY HTN-3 AND HTN-JAPAN
    Kario, K.
    Bakris, G. L.
    Bhatt, D.
    JOURNAL OF HYPERTENSION, 2015, 33 : E52 - E52
  • [37] How should data from SYMPLICITY HTN-3 be interpreted?
    Roland E. Schmieder
    Nature Reviews Cardiology, 2014, 11 : 375 - 376
  • [38] SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold?
    Staessen, Jan A.
    Jin, Yu
    Persu, Alexandre
    JOURNAL OF BIOMEDICAL RESEARCH, 2014, 28 (02): : 73 - 74
  • [39] Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
    Kandzari, David E.
    Bhatt, Deepak L.
    Brar, Sandeep
    Devireddy, Chandan M.
    Esler, Murray
    Fahy, Martin
    Flack, John M.
    Katzen, Barry T.
    Lea, Janice
    Lee, David P.
    Leon, Martin B.
    Ma, Adrian
    Massaro, Joseph
    Mauri, Laura
    Oparil, Suzanne
    O'Neill, William W.
    Patel, Manesh R.
    Rocha-Singh, Krishna
    Sobotka, Paul A.
    Svetkey, Laura
    Townsend, Raymond R.
    Bakris, George L.
    EUROPEAN HEART JOURNAL, 2015, 36 (04) : 219 - 227
  • [40] SYMPLICITY HTN-3: failure at 6 months, success at 3 years?
    Fanelli, Elvira
    Persu, Alexandre
    LANCET, 2022, 400 (10361): : 1382 - 1383
12345